Global Blood Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Global Blood Therapeutics's estimated annual revenue is currently $179.9M per year.
- Global Blood Therapeutics received $115.0M in venture funding in December 2017.
- Global Blood Therapeutics's estimated revenue per employee is $913,401
- Global Blood Therapeutics's total funding is $532.5M.
- Global Blood Therapeutics's current valuation is $1.9B. (January 2022)
Employee Data
- Global Blood Therapeutics has 197 Employees.
- Global Blood Therapeutics grew their employee count by -60% last year.
Global Blood Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | VP Intellectual Property | Reveal Email/Phone |
3 | VP, Government Affairs and Policy | Reveal Email/Phone |
4 | VP Sales and Market Access | Reveal Email/Phone |
5 | VP, Regulatory Affairs | Reveal Email/Phone |
6 | Head Regulatory Operations, Submission Management and Publishing | Reveal Email/Phone |
7 | Head Regulatory Affairs, Europe & GCC | Reveal Email/Phone |
8 | EVP and Head Research and Development | Reveal Email/Phone |
9 | SVP, Operations | Reveal Email/Phone |
10 | Head Legal and Compliance, Europe | Reveal Email/Phone |
Global Blood Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Global Blood Therapeutics?
Global Blood Therapeutics (GBT) (NASDAQ: GBT), based in South SF, is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. We aim to make a significant impact by treating the root cause or making a meaningful difference in the standards of care. Through in-licensing and continued research and development, were committed to Hope+Science+Community. You can view our social community guidelines at http://www.gbt.com/about/social-community-guidelines/
keywords:Biotechnology,Healthcare,Pharmaceuticals
$532.5M
Total Funding
197
Number of Employees
$179.9M
Revenue (est)
-60%
Employee Growth %
$1.9B
Valuation
N/A
Accelerator
Global Blood Therapeutics News
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical...
Global Blood Therapeutics had a negative net margin of 155.63% and a negative return on equity of 102.42%. The business had revenue of $56.10...
Global Blood Therapeutics (GBT) is developing new therapeutics for blood disorders, chiefly sickle cell disease (SCD), while also rallying...
PDF Version SOUTH SAN FRANCISCO, Calif. - October 29, 2021 - Global Blood Therapeutics, Inc. (GBT) was deeply saddened to learn that our dear friend and sickle cell warrior Hertz Nazaire passed away today. Our thoughts are with his family and friends during this difficult time. Hertz was an ar ...
SOUTH SAN FRANCISCO - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the company's supplemental New Drug Application (sNDA) seeking accelerated approval for Oxbryta (voxelotor) for the treatment of ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $31.5M | 203 | 1% | N/A |
#2 | $199.8M | 206 | 28% | $333.1M |
#3 | $60.2M | 218 | 0% | N/A |
#4 | $11.5M | 222 | 48% | $190M |
#5 | $34.6M | 223 | -4% | $264.5M |
Global Blood Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-01-07 | $48.0M | B | Multiple | Article |
| 2016-06-21 | $115.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2016-06-27 | $112.3M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2017-02-23 | $125.0M | Undisclosed | Cantor Fitzgerald & Co | Article |
| 2017-03-01 | $143.8M | Undisclosed | Cantor Fitzgerald & Co | Article |
| 2017-12-18 | $115.0M | Undisclosed | Cantor Fitzgerald & Co. | Article |